SMI of Bcl-2 TW-37 is active across a spectrum of B-cell tumors irrespective of their proliferative and differentiation status

Journal of Hematology and Oncology

Volumn 2, Issue , 2009, Pages

  Al Katib, Ayad M ^a   Sun, Yuan ^a   Goustin, Anton Scott ^a   Azmi, Asfar Sohail ^a   Chen, Ben ^a   Aboukameel, Amro ^a   Mohammad, Ramzi M ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIM PROTEIN; CASPASE 3; CASPASE 9; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; TW 37; UNCLASSIFIED DRUG; BENZAMIDE DERIVATIVE; SULFONE; TW 37 COMPOUND; TW-37 COMPOUND;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CANCER INHIBITION; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; DNA FRAGMENTATION; DRUG EFFICACY; DRUG STRUCTURE; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; IC 50; MOUSE; NONHUMAN; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; TUMOR GROWTH; ANIMAL; B CELL LEUKEMIA; CHEMISTRY; DISEASE COURSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; INSTITUTE FOR CANCER RESEARCH MOUSE; MOLECULAR WEIGHT; MOUSE MUTANT; PATHOLOGY; TREATMENT OUTCOME; TUMOR CELL CULTURE;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZAMIDES; CELL DIFFERENTIATION; CELL PROLIFERATION; DISEASE PROGRESSION; FEMALE; HUMANS; LEUKEMIA, B-CELL; MICE; MICE, INBRED ICR; MICE, SCID; MOLECULAR WEIGHT; PROTO-ONCOGENE PROTEINS C-BCL-2; SULFONES; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 67749143838     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-2-8     Document Type: Article

References (43)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Xu J, Thun MJ: Cancer statistics 2008. CA Cancer J Clin 2008, 58:71-96.
2. Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadie M, Spinelli JJ, Costantini AS, Rudiger T, Scarpa A, Zheng T, Weisenberger DD: Proposed classification of lymphoid neoplasms for epidemiologic research from the International Lymphoma Epidemiology Consortium (Inter Lymph). Blood 2007, 110:695-708.
3. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999, 17:3835-49.
4. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De-Wolf-Peeters C, Falini B, Gatter KC: A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994, 84:1361-92.
5. Al-Katib AM, Mohammad RM: Differentiation of human B-cell tumors, a preclinical model for differentiation therapy. In Basic and Clinical Applications of Flow Cytometry Edited by: Valeriote FA, Nakeff A, Valdivieso M. Kluwer Academic Publishers Group; 1996.
6. Armitage JO, Weisenburger DD: New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998, 16:2780-95.
7. Iqbal J, Sanger, Horsman DE, Rosenwald A, Pickering DL, Dave B, Dave S, Xiao L, Cao K, Zhu Q, Sherman S, Hans CP, Weisenberger DD, Greiner TC, Gascoyne RD, Ott G, Muller-Hermelink HK, Delabie J, Braziel RM, Jaffe ES, Campo E, Lynch JC, Connors JM, Vose JO, Armitage JO, Grogan TM, Staudt LM, Chan WC: BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma. Am J Pathol 2004, 165:159-166.
8. Huang JZ, Sanger WG, Greiner TC, Staudt LM, Weisenberger DD, Pickering DL, Lynch JC, Armitage JO, Warnke RA, Alizadeh AA, Lossoss IS, Levy R, Chan WC: The t (14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. Blood 2002, 99:2285-90.
9. Konopleva M, Zhao S, Xie Z, Segall H, Younes A, Claxton DF, Estrov Z, Kornblau SM, Andreeff M: Apoptosis. Molecules and mechanisms. Adv Exp Med Biol 1999, 457:217-236.
10. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, Joseph MK, Kitada S, Korsmeyer SJ, Kunzer AR, Letai A, Li C, Mitten MJ, Nettesheim DG, Ng S, Nimmer PM, O'Connor JM, Oleksijew A, Petros AM, Reed JC, Shen W, Tahir SK, Thompson CB, Tomaselli KJ, Wang B, Wendt MD, Zhang H, Fesik SW, Rosenberg SH: An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005, 435:677-681.
11. Ding K, Lu Y, Nikolovska-Coleska Z, Wang G, Qiu S, Shangary S, Gao W, Qin D, Stuckey J, Krajewski K, Roller PP, Wang S: Structurebased design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction. J Med Chem 2006, 49:3432-35.
12. Karl E, Warner K, Zeitlin B, Kaneko T, Wurtzel L, Jin T, Chang J, Wang S, Wang CY, Strieter RM, Nunez G, Polverini PJ, Nor JE: Bcl-2 acts in a proangiogenic signaling pathway through nuclear factor-kappaB and CXC chemokines. Cancer Res 2005, 65:5063-69.
13. Perez-Galan P, Roue G, Villamor N, Campo E, Colomer D: The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak. Blood 2007, 109:4441-49.
14. Wang G, Nikolovska-Coleska Z, Yang CY, Wang R, Tang G, Guo J, Shangary S, Qiu S, Gaor W, Yang D, Meagher J, Stuckey J, Krajewski K, Jiang S, Roller PP, Abaan HO, Tomita Y, Wang S: Structurebased design of potent small-molecule inhibitors of antiapoptotic Bcl-2 proteins. J Med Chem 2006, 49:6139-42.
15. Shivakumar L, Armitage JO: Bcl-2 gene expression as a predictor of outcome in diffuse large B-cell lymphoma. Clin Lymphoma Myeloma 2006, 6:455-57.
16. ten Berge RL, Meijer CJ, Dukers DF, Kummer JA, Bladergroen BA, Vos W, Hack CE, Ossenkoppele GJ, Oudejans JJ: Expression levels of apoptosis-related proteins predict clinical outcome in anaplastic large cell lymphoma. Blood 2002, 99:4540-46.
17. Gascoyne RD, Adomat SA, Krajewski S, Connors JM, Reed JC: Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 1997, 90:244-251.
18. Hill ME, MacLennan KA, Cunningham DC, Vaughan BH, Burke M, Clarke P, De Stefano F, Anderson L, Vaughan GH, Mason D, Selby P, Linch DC: Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: a British National Lymphoma Investigation Study. Blood 1996, 88:1046-1051.
19. Pulley H, Mohammad R: Small molecule inhibitors of Bcl-2 protein. Drugs of the Future 2004, 29:369-81.
20. Al-Katib AM, Smith MR, Kamanda WS, Pettit GR, Hamdan M, Mohamed AN, Chelladurai B, Mohammad RM: Bryostatin 1 downregulates mdr1 and potentiates vincristine cytotoxicity in diffuse large cell lymphoma xenografts. Clin Cancer Res 1998, 4:1305-14.
21. Mohammad RM, Mohamed AN, Smith MR, Jawadi NS, Al-Katib A: A unique EBV-negative low-grade lymphoma line (WSU-FSCCL) exhibiting both t (14;18) and t (8;11). Cancer Genet Cytogenet 1993, 70:62-67.
22. Mohammad R, Abubakr Y, Dan M, Aboukameel A, Chow C, Mohamed A, Hamdy A, Al-Katib A: Bcl-2 antisense oligonucleotides are effective against systemic but not central nervous system disease in severe combined immunodeficient mice bearing human t (14;18) follicular lymphoma. Clin Cancer Res 2002, 8:1277-83.
23. Al-Katib A, Mohammad R, Hamdan M, Mohamed AN, Dan M, Smith MR: Propagation of Waldenstrom's macroglobulinemia cells in vitro and in severe combined immune deficient mice: utility as a preclinical drug screening model. Blood 1993, 81:3034-42.
24. McGahon AJ, Martin SJ, Bissonnette RP, Mahboubi A, Shi Y, Mogil RJ, Nishioka WK, Green DR: The end of the (cell) line: methods for the study of apoptosis in vitro. Methods Cell Biol 1995, 46:153-185.
25. Mohammad RM, Wang S, Aboukameel A, Chen B, Wu X, Chen J, Al-Katib A: Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-X (L) [(-) -gossypol] against diffuse large cell lymphoma. Mol Cancer Ther 2005, 4:13-21.
26. Mohammad RM, Wall NR, Dutcher JA, Al-Katib AM: The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model. Clin Cancer Res 2000, 6:4950-56.
27. Mohammad RM, Goustin AS, Aboukameel A, Chen B, Banerjee S, Wang G, Nikolovska-Coleska Z, Wang S, Al-Katib A: Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1. Clin Cancer Res 2007, 13:2226-35.
28. Kneba M, Bergholz M, Bolz I, Hulpke M, Batge R, Schauer A, Krieger G: Heterogeneity of immunoglobulin gene rearrangements in B-cell lymphomas. Int J Cancer 1990, 45:609-613.
29. Zent CS: Chronic B-cell lymphoproliferative disorders: how many diseases? Leuk Lymphoma 2006, 47:2006-2007.
30. Ottensmeier C: The classification of lymphomas and leukemias. Chem Biol Interact 2001, 135:653-664.
31. Tsujimoto Y, Finger LR, Yunis J, Nowell PC, Croce CM: Cloning of the chromosome breakpoint of neoplastic B cells with the t (14;18) chromosome translocation. Science 1984, 226:1097-1099.
32. Mattson MP, Kroemer G: Mitochondria in cell death: novel targets for neuroprotection and cardioprotection. Trends Mol Med 2003, 9:196-205.
33. Shangary S, Johnson DE: Peptides derived from BH3 domains of Bcl-2 family members: a comparative analysis of inhibition of Bcl-2, Bcl-x (L) and Bax oligomerization, induction of cytochrome c release, and activation of cell death. Biochemistry 2002, 41:9485-95.
34. van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabator PE, Willis SN, Scott CL, Day CL, Cory S, Adams JM, Roberts AW, Huang DC: The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006, 10:389-399.
35. Konopleva M: Mechanism of apoptosis induction by chemical inhibitors of bcl-2 in acute leukemia cells. AACR 97th Annual Meeting. Washington, D. C 2006.
36. Craig RW: MCL1 provides a window on the role of the BCL2 family in cell proliferation, differentiation and tumorigenesis. Leukemia 2002, 16:444-454.
37. Michels J, Foria V, Mead B, Jackson G, Mullee M, Johnson PW, Packham G: Immunohistochemical analysis of the antiapoptotic Mcl-1 and Bcl-2 proteins in follicular lymphoma. Br J Haematol 2006, 132:743-746.
38. Cho-Vega JH, Rassidakis GZ, Admirand JH, Oyarzo M, Ramalingam P, Paraguya A, McDonnell TJ, Amin HM, Medeiros LJ: MCL-1 expression in B-cell non-Hodgkin's lymphomas. Hum Pathol 2004, 34:1095-1100.
39. Cuconati A, Mukherjee C, Perez D, White E: DNA damage response and MCL-1 destruction initiate apoptosis in adenovirus-infected cells. Genes Dev 2003, 17:2922-32.
40. Korsmeyer SJ, Shutter JR, Veis DJ, Merry DE, Oltvai ZN: Bcl-2/Bax: a rheostat that regulates an anti-oxidant pathway and cell death. Semin Cancer Biol 1993, 4:327-332.
41. Oltvai ZN, Milliman CL, Korsmeyer SJ: Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993, 74:609-619.
42. Yang E, Korsmeyer SJ: Molecular thanatopsis: a discourse on the BCL2 family and cell death. Blood 1996, 88:M386-401.
43. Goustin AS, Giri A, Wang S, Al-Katib A, Mohammad RM: Surface plasmon resonance study of apoptotic regulators Bcl-2, Bclw, Bcl-XL, and Mcl-1 indicate that the preclinical small molecule inhibitor (SMI) TW-37 binds to the hydrophobic groove competitively with tBid to form a heterodimer which cannot be disrupted by 200-fold molar excess of TW-37 [Abstract 951045]. 49th Annual ASH meeting 2007.